Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic the GLP ...

The problem is that these Glucagon-like peptide-1 (GLP-1 ... on their use in these patients,” senior researcher Dr. Jung-Im Shin, an associate professor at Johns Hopkins Bloomberg School ...

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

Injectable glucagon has been the primary treatment ... Giving the drug by subcutaneous or intramuscular injection requires training however as it needs to be mixed in a several-step process ...

IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem ...

In one study, seven patients (26%) presenting with foot drop had had recent IM injections in the buttock. An additional 20 patients (74%) presented much later (Fatunde & Familusi, 2001).

For moderate to severe hypoglycemia due to diabetes, a prescription medication containing the hormone glucagon can be delivered by injection or nasal inhalation. Hypoglycemic emergencies, in which ...